https://www.selleckchem.com/pr....oducts/agi-24512.htm
Patients receiving escitalopram had significantly higher sexual dysfunction as compared to healthy controls in mean total FSFI score (P less then 0.001) and all mean domain scores of FSFI except pain. Interpretation conclusions A significant proportion of sexually active females with depression currently in remission, receiving escitalopram, reported dysfunction in all domains of sexual function; thus, routine screening for sexual dysfunction during follow up is advisable for early identification and prompt treatment.Background
Like
Comment
Share
